{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:39:14Z","timestamp":1778575154396,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"DOI":"10.7759\/cureus.78513","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:03:06Z","timestamp":1738713786000},"source":"Crossref","is-referenced-by-count":1,"title":["Letrozole Cotreatment Reduces Unexpectedly Poor Responses in Ovarian Stimulation With Follitropin Delta: A Strategy to Prevent High Anti-M\u00fcllerian Hormone (AMH) but Poor Response"],"prefix":"10.7759","author":[{"given":"Hiromasa","family":"Kuroda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Shibaike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Haruki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.08.907","article-title":"Establishing the follitropin delta dose providing comparable ovarian response as 150 IU\/day follitropin alfa for controlled ovarian stimulation","volume":"114","author":"Arce JC","year":"2020","unstructured":"Arce JC, Larsson P. Establishing the follitropin delta dose providing comparable ovarian response as 150 IU\/day follitropin alfa for controlled ovarian stimulation. Fertil Steril. 2020, 114:335-6. 10.1016\/j.fertnstert.2020.08.907","journal-title":"Fertil Steril"},{"key":"ref2","unstructured":"Follitropin delta SmPC. (2022). Accessed. July 13, 2024: https:\/\/www.medicines.org.uk\/emc\/product\/10352\/smpc."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen A","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BC, Garc\u00eda-Velasco JA, Klein BM, Arce JC. Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017, 107:387-396.e4. 10.1016\/j.fertnstert.2016.10.033","journal-title":"Fertil Steril"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara O","year":"2021","unstructured":"Ishihara O, Arce JC. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021, 42:909-18. 10.1016\/j.rbmo.2021.01.023","journal-title":"Reprod Biomed Online"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao J","year":"2021","unstructured":"Qiao J, Zhang Y, Liang X, et al.. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients. Hum Reprod. 2021, 36:2452-62. 10.1093\/humrep\/deab155","journal-title":"Hum Reprod"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.328","article-title":"Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson H","year":"2014","unstructured":"Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014, 54:1299-307. 10.1002\/jcph.328","journal-title":"J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12864","article-title":"Follicular and endocrine dose responses according to anti-M\u00fcllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049)","volume":"83","author":"Bosch E","year":"2015","unstructured":"Bosch E, Nyboe Andersen A, Barri P, et al.. Follicular and endocrine dose responses according to anti-M\u00fcllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049). Clin Endocrinol (Oxf). 2015, 83:902-12. 10.1111\/cen.12864","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2018.10.012","article-title":"Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial","volume":"38","author":"Bosch E","year":"2019","unstructured":"Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019, 38:195-205. 10.1016\/j.rbmo.2018.10.012","journal-title":"Reprod Biomed Online"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0129-9","article-title":"Population pharmacokinetic modelling of FE 999049, a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses","volume":"16","author":"Rose TH","year":"2016","unstructured":"Rose TH, R\u00f6shammar D, Erichsen L, Grundemar L, Ottesen JT. Population pharmacokinetic modelling of FE 999049, a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses. Drugs R D. 2016, 16:173-80. 10.1007\/s40268-016-0129-9","journal-title":"Drugs R D"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13956","article-title":"Anti-M\u00fcllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta","volume":"90","author":"Nelson SM","year":"2019","unstructured":"Nelson SM, Larsson P, Mannaerts BM, Nyboe Andersen A, Fauser BC. Anti-M\u00fcllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta. Clin Endocrinol (Oxf). 2019, 90:719-26. 10.1111\/cen.13956","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-021-02271-5","article-title":"Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta","volume":"38","author":"Havelock J","year":"2021","unstructured":"Havelock J, Aaris Henningsen AK, Mannaerts B, Arce JC. Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta. J Assist Reprod Genet. 2021, 38:2651-61. 10.1007\/s10815-021-02271-5","journal-title":"J Assist Reprod Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.12.013","article-title":"An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta","volume":"44","author":"Bachmann A","year":"2022","unstructured":"Bachmann A, Kissler S, Laubert I, et al.. An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta. Reprod Biomed Online. 2022, 44:853-7. 10.1016\/j.rbmo.2021.12.013","journal-title":"Reprod Biomed Online"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.08.017","article-title":"In\u00a0vitro fertilization treatments with the use of clomiphene citrate or letrozole","volume":"108","author":"Haas J","year":"2017","unstructured":"Haas J, Casper RF. In\u00a0vitro fertilization treatments with the use of clomiphene citrate or letrozole. Fertil Steril. 2017, 108:568-71. 10.1016\/j.fertnstert.2017.08.017","journal-title":"Fertil Steril"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010287.pub4","article-title":"Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome","volume":"9","author":"Franik S","year":"2022","unstructured":"Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022, 9:CD010287. 10.1002\/14651858.CD010287.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg311","article-title":"Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility","volume":"18","author":"Mitwally MF","year":"2003","unstructured":"Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod. 2003, 18:1588-97. 10.1093\/humrep\/deg311","journal-title":"Hum Reprod"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1028-4559(10)60064-2","article-title":"GnRH antagonist\/letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization","volume":"49","author":"Davar R","year":"2010","unstructured":"Davar R, Oskouian H, Ahmadi S, Firouzabadi RD. GnRH antagonist\/letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization. Taiwan J Obstet Gynecol. 2010, 49:297-301. 10.1016\/S1028-4559(10)60064-2","journal-title":"Taiwan J Obstet Gynecol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04006.x","article-title":"Aromatase inhibitors for ovulation induction and ovarian stimulation","volume":"74","author":"Lee VC","year":"2011","unstructured":"Lee VC, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol (Oxf). 2011, 74:537-46. 10.1111\/j.1365-2265.2011.04006.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18502\/ijrm.v13i4.6891","article-title":"Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: an RCT","volume":"18","author":"Eftekhar M","year":"2020","unstructured":"Eftekhar M, Saeed L. Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: an RCT. Int J Reprod Biomed. 2020, 18:287-94. 10.18502\/ijrm.v13i4.6891","journal-title":"Int J Reprod Biomed"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab249","article-title":"Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial","volume":"37","author":"B\u00fclow NS","year":"2022","unstructured":"B\u00fclow NS, Skouby SO, Warzecha AK, et al.. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial. Hum Reprod. 2022, 37:309-21. 10.1093\/humrep\/deab249","journal-title":"Hum Reprod"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.12.006","article-title":"Co-treatment with letrozole during ovarian stimulation for IVF\/ICSI: a systematic review and meta-analysis","volume":"44","author":"B\u00fclow NS","year":"2022","unstructured":"B\u00fclow NS, Dreyer Holt M, Skouby SO, Birch Petersen K, Englund AL, Pinborg A, Macklon NS. Co-treatment with letrozole during ovarian stimulation for IVF\/ICSI: a systematic review and meta-analysis. Reprod Biomed Online. 2022, 44:717-36. 10.1016\/j.rbmo.2021.12.006","journal-title":"Reprod Biomed Online"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.05.003","article-title":"Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-M\u00fcllerian hormone and inhibin-B","volume":"89","author":"Andersen CY","year":"2008","unstructured":"Andersen CY, Lossl K. Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-M\u00fcllerian hormone and inhibin-B. Fertil Steril. 2008, 89:1760-5. 10.1016\/j.fertnstert.2007.05.003","journal-title":"Fertil Steril"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/gaq073","article-title":"In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA","volume":"17","author":"Nielsen ME","year":"2011","unstructured":"Nielsen ME, Rasmussen IA, Kristensen SG, et al.. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod. 2011, 17:63-70. 10.1093\/molehr\/gaq073","journal-title":"Mol Hum Reprod"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.106338","article-title":"Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial","volume":"5","author":"Kar S","year":"2012","unstructured":"Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. J Hum Reprod Sci. 2012, 5:262-5. 10.4103\/0974-1208.106338","journal-title":"J Hum Reprod Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-009-9308-8","article-title":"Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome","volume":"26","author":"Unsal T","year":"2009","unstructured":"Unsal T, Konac E, Yesilkaya E, et al.. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009, 26:205-16. 10.1007\/s10815-009-9308-8","journal-title":"J Assist Reprod Genet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35690","article-title":"Association between follicle-stimulating hormone receptor (FSHR) rs6166 and estrogen receptor 1 (ESR1) rs2234693 polymorphisms and polycystic ovary syndrome risk, phenotype, and reproductive outcomes in an infertile Portuguese population","volume":"15","author":"Vieira IH","year":"2023","unstructured":"Vieira IH, Carvalho AF, Almeida Reis S, et al.. Association between follicle-stimulating hormone receptor (FSHR) rs6166 and estrogen receptor 1 (ESR1) rs2234693 polymorphisms and polycystic ovary syndrome risk, phenotype, and reproductive outcomes in an infertile Portuguese population. Cureus. 2023, 15:e35690. 10.7759\/cureus.35690","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.04.042","article-title":"Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial","volume":"92","author":"Garcia-Velasco JA","year":"2009","unstructured":"Garcia-Velasco JA, Quea G, Pir\u00f3 M, Mayoral M, Ruiz M, Toribio M, Requena A. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril. 2009, 92:222-5. 10.1016\/j.fertnstert.2008.04.042","journal-title":"Fertil Steril"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020614","article-title":"Letrozole and ovarian hyperstimulation syndrome (OHSS): a promising prevention strategy","volume":"12","author":"Di Guardo F","year":"2023","unstructured":"Di Guardo F, Lello C, Incognito GG, Bruno MT, Palumbo M. Letrozole and ovarian hyperstimulation syndrome (OHSS): a promising prevention strategy. J Clin Med. 2023, 12:10.3390\/jcm12020614","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/19396368.2014.957879","article-title":"Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval","volume":"60","author":"He Q","year":"2014","unstructured":"He Q, Liang L, Zhang C, Li H, Ge Z, Wang L, Cui S. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014, 60:355-60. 10.3109\/19396368.2014.957879","journal-title":"Syst Biol Reprod Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.808517","article-title":"Comparison of the effectiveness of various medicines in the prevention of ovarian hyperstimulation syndrome: a network meta-analysis of randomized controlled trials","volume":"13","author":"Wu D","year":"2022","unstructured":"Wu D, Shi H, Yu Y, Yu T, Zhai J. Comparison of the effectiveness of various medicines in the prevention of ovarian hyperstimulation syndrome: a network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022, 13:808517. 10.3389\/fendo.2022.808517","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2019.101643","article-title":"The role of letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study","volume":"49","author":"Tshzmachyan R","year":"2020","unstructured":"Tshzmachyan R, Hambartsoumian E. The role of letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study. J Gynecol Obstet Hum Reprod. 2020, 49:101643. 10.1016\/j.jogoh.2019.101643","journal-title":"J Gynecol Obstet Hum Reprod"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/338771-letrozole-cotreatment-reduces-unexpectedly-poor-responses-in-ovarian-stimulation-with-follitropin-delta-a-strategy-to-prevent-high-anti-mllerian-hormone-amh-but-poor-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:03:08Z","timestamp":1738713788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/338771-letrozole-cotreatment-reduces-unexpectedly-poor-responses-in-ovarian-stimulation-with-follitropin-delta-a-strategy-to-prevent-high-anti-mllerian-hormone-amh-but-poor-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.78513","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}